CN115315265A - 线粒体用于促进伤口修复及/或伤口愈合的用途 - Google Patents

线粒体用于促进伤口修复及/或伤口愈合的用途 Download PDF

Info

Publication number
CN115315265A
CN115315265A CN202180014788.XA CN202180014788A CN115315265A CN 115315265 A CN115315265 A CN 115315265A CN 202180014788 A CN202180014788 A CN 202180014788A CN 115315265 A CN115315265 A CN 115315265A
Authority
CN
China
Prior art keywords
mitochondria
wound
composition
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180014788.XA
Other languages
English (en)
Other versions
CN115315265B (zh
Inventor
郑汉中
许智凯
曾惠卿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Chung Hsing University
Original Assignee
National Chung Hsing University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Chung Hsing University filed Critical National Chung Hsing University
Publication of CN115315265A publication Critical patent/CN115315265A/zh
Application granted granted Critical
Publication of CN115315265B publication Critical patent/CN115315265B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02—Blood transfusion apparatus
    • A61M1/029—Separating blood components present in distinct layers in a container, not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/115—Platelets, megakaryocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

一种包含一线粒体及一血液制品的组合物及其用途，该血液制品中含有至少一生长因子，具体为一富含血小板纤维蛋白；该用途为一种线粒体作为制备修复伤口或促进伤口愈合的组合物的用途，以及一种线粒体作为制备促进组织再生的组合物的用途。

Description

PCT国内申请，说明书已公开。

Claims (9)

  1. PCT国内申请，权利要求书已公开。
CN202180014788.XA 2020-03-20 2021-03-19 线粒体用于促进伤口修复及/或伤口愈合的用途 Active CN115315265B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062992546P 2020-03-20 2020-03-20
US62/992,546 2020-03-20
PCT/CN2021/081685 WO2021185340A1 (zh) 2020-03-20 2021-03-19 线粒体用于促进伤口修复及/或伤口愈合的用途

Publications (2)

Publication Number Publication Date
CN115315265A true CN115315265A (zh) 2022-11-08
CN115315265B CN115315265B (zh) 2024-05-31

Family

ID=

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009002811A2 (en) * 2007-06-22 2008-12-31 Children's Medical Center Corporation Therapeutic platelet compositions and methods
US20110008458A1 (en) * 2009-07-09 2011-01-13 Orogen Biosciences, Inc. Process for removing growth factors from platelets
US20130022666A1 (en) * 2011-07-20 2013-01-24 Anna Brzezinska Methods and compositions for transfer of mitochondria into mammalian cells
US20140193511A1 (en) * 2011-09-11 2014-07-10 Minovia Therapeutics Ltd. Compositions Of Functional Mitochondria And Uses Thereof
TW201509425A (zh) * 2013-09-13 2015-03-16 Taichung Hospital Ministry Of Health And Welfare 以血液製備修復傷口用醫藥組合物之方法
US20150079193A1 (en) * 2012-05-16 2015-03-19 Minovia Therapeutic Ltd. Compositions and methods for inducing angiogenesis
CN105477018A (zh) * 2015-12-07 2016-04-13 深圳爱生再生医学科技有限公司 修复皮肤溃疡的干细胞制剂及其制备方法
CN105520891A (zh) * 2014-09-30 2016-04-27 李德财 以外源性线粒体为有效成份的组合物、其用途及修复细胞的方法
CN106029102A (zh) * 2015-01-15 2016-10-12 小威廉·K·博斯 使用富血小板血浆进行组织的修复和复壮
US20180057610A1 (en) * 2016-01-15 2018-03-01 Children's Medical Center Corporation Therapeutic Use of Mitochondria and Combined Mitochondrial Agent
CN108495659A (zh) * 2015-11-02 2018-09-04 韦里格拉福特公司 用于伤口愈合的组合物和方法
WO2018212758A1 (en) * 2017-05-15 2018-11-22 Miron Richard J Liquid platelet-rich fibrin as a carrier system for biomaterials and biomolecules
US20190008896A1 (en) * 2017-07-07 2019-01-10 Richard Postrel Methods and Systems for the Prevention, Treatment and Management of Disease and Effects of Aging Via Cell-to-Cell Restoration Therapy Using Subcellular Transactions
WO2019151840A1 (ko) * 2018-02-02 2019-08-08 주식회사 파이안바이오테크놀로지 분리된 미토콘드리아를 포함하는 류마티스 관절염 예방 또는 치료용 약학 조성물
US20200009198A1 (en) * 2016-11-30 2020-01-09 Paean Biotechnology Inc. Pharmaceutical compostion containing mitochondria
WO2020021541A1 (en) * 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy with stem cells enriched with functional mitochondria
WO2020054829A1 (ja) * 2018-09-14 2020-03-19 ルカ・サイエンス株式会社 ミトコンドリアのリンパ器官への移植およびそのための組成物

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009002811A2 (en) * 2007-06-22 2008-12-31 Children's Medical Center Corporation Therapeutic platelet compositions and methods
US20110008458A1 (en) * 2009-07-09 2011-01-13 Orogen Biosciences, Inc. Process for removing growth factors from platelets
US20130022666A1 (en) * 2011-07-20 2013-01-24 Anna Brzezinska Methods and compositions for transfer of mitochondria into mammalian cells
US20140193511A1 (en) * 2011-09-11 2014-07-10 Minovia Therapeutics Ltd. Compositions Of Functional Mitochondria And Uses Thereof
US20150079193A1 (en) * 2012-05-16 2015-03-19 Minovia Therapeutic Ltd. Compositions and methods for inducing angiogenesis
TW201509425A (zh) * 2013-09-13 2015-03-16 Taichung Hospital Ministry Of Health And Welfare 以血液製備修復傷口用醫藥組合物之方法
CN105520891A (zh) * 2014-09-30 2016-04-27 李德财 以外源性线粒体为有效成份的组合物、其用途及修复细胞的方法
CN106029102A (zh) * 2015-01-15 2016-10-12 小威廉·K·博斯 使用富血小板血浆进行组织的修复和复壮
CN108495659A (zh) * 2015-11-02 2018-09-04 韦里格拉福特公司 用于伤口愈合的组合物和方法
CN105477018A (zh) * 2015-12-07 2016-04-13 深圳爱生再生医学科技有限公司 修复皮肤溃疡的干细胞制剂及其制备方法
US20180057610A1 (en) * 2016-01-15 2018-03-01 Children's Medical Center Corporation Therapeutic Use of Mitochondria and Combined Mitochondrial Agent
CN109152795A (zh) * 2016-01-15 2019-01-04 儿童医学中心公司 线粒体和组合的线粒体试剂的治疗用途
US20200009198A1 (en) * 2016-11-30 2020-01-09 Paean Biotechnology Inc. Pharmaceutical compostion containing mitochondria
WO2018212758A1 (en) * 2017-05-15 2018-11-22 Miron Richard J Liquid platelet-rich fibrin as a carrier system for biomaterials and biomolecules
US20190008896A1 (en) * 2017-07-07 2019-01-10 Richard Postrel Methods and Systems for the Prevention, Treatment and Management of Disease and Effects of Aging Via Cell-to-Cell Restoration Therapy Using Subcellular Transactions
WO2019151840A1 (ko) * 2018-02-02 2019-08-08 주식회사 파이안바이오테크놀로지 분리된 미토콘드리아를 포함하는 류마티스 관절염 예방 또는 치료용 약학 조성물
WO2020021541A1 (en) * 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy with stem cells enriched with functional mitochondria
WO2020054829A1 (ja) * 2018-09-14 2020-03-19 ルカ・サイエンス株式会社 ミトコンドリアのリンパ器官への移植およびそのための組成物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AMANEH MOHAMMADI ROUSHANDEH等: "Mitochondrial transplantation as a potential and novel master key for treatment of various incurable diseases", CYTOTECHNOLOGY, vol. 71, no. 2, pages 647 - 663, XP036759622, DOI: 10.1007/s10616-019-00302-9 *
何赤东;刘丽忠;: "富血小板纤维蛋白在促进软组织损伤愈合中的临床研究进展", 南昌大学学报(医学版), no. 02, 28 April 2015 (2015-04-28) *
李艳秋等: "PRF制备方法研究进展", vol. 21, no. 1, pages 47 - 49 *
罗晓丁;李丹;张剑明;: "富血小板纤维蛋白促进组织愈合机制的探讨", 中国口腔种植学杂志, no. 04, 27 December 2011 (2011-12-27) *
陈丽等: "线粒体对创面修复的作用研究", vol. 27, no. 11, pages 4 - 5 *

Also Published As

Publication number Publication date
CN115135328B (zh) 2024-01-02
TWI796653B (zh) 2023-03-21
JP2023518083A (ja) 2023-04-27
CN115335065A (zh) 2022-11-11
TWI789724B (zh) 2023-01-11
WO2021185340A1 (zh) 2021-09-23
EP4122444A1 (en) 2023-01-25
WO2021185377A1 (zh) 2021-09-23
TWI787761B (zh) 2022-12-21
TWI787763B (zh) 2022-12-21
TW202404618A (zh) 2024-02-01
US20230016499A1 (en) 2023-01-19
CN115135328A (zh) 2022-09-30
CN117379458A (zh) 2024-01-12
US20230042445A1 (en) 2023-02-09
US20230023218A1 (en) 2023-01-26
TWI827321B (zh) 2023-12-21
TW202135838A (zh) 2021-10-01
WO2021185364A1 (zh) 2021-09-23
WO2021185341A1 (zh) 2021-09-23
CN115315248A (zh) 2022-11-08
US20230165899A1 (en) 2023-06-01
EP4122474A1 (en) 2023-01-25
TW202306576A (zh) 2023-02-16
TW202135839A (zh) 2021-10-01
WO2021185376A1 (zh) 2021-09-23
TW202200781A (zh) 2022-01-01
CN115297872B (zh) 2024-03-29
TW202135836A (zh) 2021-10-01
TW202135837A (zh) 2021-10-01
TW202135779A (zh) 2021-10-01
EP4122474A4 (en) 2024-05-01
CN115103683A (zh) 2022-09-23
WO2021185342A1 (zh) 2021-09-23
CN117357559A (zh) 2024-01-09
US20230137870A1 (en) 2023-05-04
TWI789723B (zh) 2023-01-11
US20230023438A1 (en) 2023-01-26
CN115103683B (zh) 2024-04-09
TW202308668A (zh) 2023-03-01
CN115297872A (zh) 2022-11-04
EP4122444A4 (en) 2024-04-17

Similar Documents

Publication Publication Date Title
AU2014238305B2 (en) Methods and non-immunogenic compositions for treating inflammatory disorders
US10441634B2 (en) Treatment of peripheral vascular disease using protein solutions
EP3862009A1 (en) Composition for skin regeneration and wound healing, comprising induced exosomes
AU2014238367B2 (en) Treatment of pain using protein solutions
AU2014237269B2 (en) Treatment of collagen defects using protein solutions
AU2014216415B2 (en) Serum fraction of platelet-rich fibrin
Devereaux et al. Effects of platelet-rich plasma and platelet-poor plasma on human dermal fibroblasts
US20190192576A1 (en) Adipose derived stem cell exosomes and uses thereof
EP3258945B1 (en) Modified blood clots
RU2644650C2 (ru) Материал стволовых клеток и способ его получения
CN115315265A (zh) 线粒体用于促进伤口修复及/或伤口愈合的用途
Sultana et al. Efficacy and safety of platelet rich plasma therapy in male androgenetic alopecia
CN115315265B (zh) 线粒体用于促进伤口修复及/或伤口愈合的用途
Lai et al. Combination of PDGF-BB and adipose-derived stem cells accelerated wound healing through modulating PTEN/AKT pathway
WO2020174005A1 (en) Regenerative combination of plasma and adipose tissue
WO2012174529A2 (en) Methods for increasing the potency and efficacy of stem cells
KR20090119428A (ko) 상처 치료 또는 상처 치료 촉진용 약학 조성물
KR20230170735A (ko) 피부 흉터 치료

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant